Ascochlorin derivatives as ligands for nuclear hormone receptors

Journal of Medicinal Chemistry

Volumn 46, Issue 19, 2003, Pages 4113-4123

  Togashi, Marie ^a,e   Ozawa, Satoshi ^a   Abe, Shoko ^b   Nishimura, Tomoyuki ^b   Tsuruga, Mie ^a   Ando, Kunio ^c   Tamura, Gakuzo ^c   Kuwahara, Shigefumi ^b   Ubukata, Makoto ^d   Magae, Junji ^a  

^a INSTITUTE OF RESEARCH AND INNOVATION   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c KSP   (Japan)

^d TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4 FORMYL 5 METHOXY 3 METHYL 6 [3 METHYL 5 (1,2,6 TRIMETHYL 3 OXOCYCLOHEXYL) 2,4 PENTADIENYL]PHENYLPYRIDINE 4 CARBOXYLATE; 3 CHLORO 4,6 DIHYDROXY 2 METHYL 5 [7 (2,2 DIMETHYL 3 OXO 2,3 DIHYDROFURAN 5 YL) 3 METHYL 2,6 OCTADIENYL]BENZALDEHYDE; 4 O CARBOXYMETHYLASCOCHLORIN; [2 CHLORO 4 FORMYL 5 METHOXY [3 METHYL 6 (3 METHYL 1,2,6 TRIMETHYL 3 OXOCYCLOHEXYL) 2,4 PENTADIENYL]PHENOXY]ACETIC ACID; ANDROGEN RECEPTOR; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; ASCOCHLORIN DERIVATIVE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; RETINOIC ACID; STEROID HORMONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGAND BINDING; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ALKENES; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; FIBROBLASTS; FURANS; GENES, REPORTER; GENETIC VECTORS; GLYCOLATES; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MICE; MODELS, MOLECULAR; OSTEOSARCOMA; PHENOLS; PLASMIDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0141567443     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0205649     Document Type: Article

References (49)

1. Tamura, G.; Suzuki, S.; Takatsuki, A.; Ando, K.; Arima, K. Ascochlorin, a new antibiotic, found by paper-disc agar diffusion method. I) isolation, biological and chemical properties of ascochlorin. J. Antibiot. 1968, 21, 539-544.
2. Sawada, M.; Hosokawa, T.; Okutomi, T.; Ando, K. Hypolipidemic property of ascofuranone. J. Antibiot. 1973, 26, 681-686.
3. Hosokawa, T.; Suzuki, K.; Okutomi, T.; Sawada, N.; Ando, K. Effect of ascofuranone on serum lipids of rats fed a cholesterol rich diet. Jpn. J. Pharmacol. 1975, 25, 35-39.
4. Hosokawa, T.; Sawada, M.; Ando, K.; Tamura, G. Enhanced excretion of fecal neutral sterols and the hypocholesterolemic properties of 4-O-methylascochlorin. Agric. Biol. Chem. 1980, 44, 2461-2468.
5. Hosokawa, T.; Sawada, M.; Ando, K.; Tamura, G. Alteration of cholesterol metabolism by 4-O-methylascochlorin in rats. Lipids 1981, 16, 433-438.
6. Hosokawa, T.; Ando, K.; Tamura, G. Alteration of cholesterol metabolism and hypocholesterolemic property of 4-O-methylascochlorin on controlled reverse-phase feeding rats. Agric. Biol. Chem. 1982, 46, 775-781.
7. Hosokawa, T.; Ando, K.; Tamura, G. An ascochlorin derivative, AS-6, potentiates insulin action in streptozotocin diabetic mice and rats. Agric. Biol. Chem. 1982, 46, 775-781.
8. Hosokawa, T.; Ando, K.; Tamura, G. An ascochlorin derivative, AS-6, reduces insulin resistance in the genetically obese diabetic mouse, db/db. Diabetes 1985, 34, 267-274.
9. Hosokawa, T.; Ando, K.; Tamura, G. Modification of fatty acid composition in adipocyte plasma membranes by treatment with a new antidiabetic agent, AS-6, in genetically obese diabetic mice, db/db. Biochim. Biophys. Acta 1985, 834, 130-133.
10. Hosokawa, T.; Ando, K.; Tamura, G. Structural and functional abnormalities in the adipocyte plasma membrane from db/db mouse, and the effect on the abnormalities of oral treatment with AS-6. Biochem. Biophys. Res. Commun. 1984, 125, 64-69.
11. 2+ binding on the plasma membrane of adipocytes in db/db mice. Biochem. Biophys. Res. Commun. 1985, 127, 247-253.
12. Hosokawa, T.; Okutomi, T.; Sawada, M.; Ando, K.; Tamura, G. Unusual concentration of urine and prevention of polydipsia by fungal metabolites in DOCA hypertensive rats. Eur. J. Pharmacol. 1981, 69, 429-438.
13. Magae, J.; Hosokawa, T.; Ando, K.; Nagai, K.; Tamura, G. Antitumor protective property of an isoprenoid antibiotic, ascofuranone. J. Antibiot. 1982, 35, 1547-1552.
14. Magae, J.; Hayasaki, J.; Matsuda, Y.; Hotta, M.; Hosokawa, T.; Suzuki, S.; Nagai, K.; Ando, K.; Tamura, G. Antitumor and antimetastatic activity of an antibiotic, ascofuranone, and activation of phagocytes. J. Antibiot. 1988, 41, 959-965.
15. Magae, J.; Suzuki, S.; Nagai, K.; Yamasaki, M.; Ando, K.; Tamura, G. In vitro effects of an antitumor antibiotic, ascofuranone, on the murine immune system. Cancer Res. 1986, 46, 1073-1078.
16. Magae, J.; Hotta, M.; Nagai, K.; Suzuki, S.; Ando, K.; Yamasaki, M.; Tamura, G. Activation of natural cytotoxic activity and concomitant reduction of triglyceride content of murine spleen, treated with an antitumor antibiotic, ascofuranone. J. Antibiot. 1986, 39, 676-681.
17. Magae, J.; Nagai, K.; Ando, K.; Tamura, G. Differentiation of mouse and human myeloid leukemia cells induced by an antitumor antibiotic, ascofuranone. Agric. Biol. Chem. 1988, 52, 3143-3147.
18. Togashi, M.; Masuda, H.; Kawada, T.; Tanaka, M.; Saida, K.; Ando, K.; Tamura, G.; Magae, J. PPARγ activation and adipocyte differentiation induced by AS-6, a prenyl-phenol antidiabetic antibiotic. J. Antibiot. 2002, 55, 417-422.
19. Rosen, E. D.; Walkey, C. J.; Puigserver, P.; Spiegelman, B. M. Transcriptional regulation of adipogenesis. Genes Dev. 2000, 14, 1293-1307.
20. Rosen, E. D.; Spiegelman, B. M. PPARγ: a nuclear receptor of metabolism, differentiation, and cell growth. J. Biol. Chem. 2001, 276, 37731-37734.
21. Perimann, T.; Evans, R. M. Nuclear receptors in Sicily: all in the famiglia. Cell 1997, 90, 391-397.
22. Chawla, A.; Repa, J. J.; Evans, R. M.; Mangelsdorf, D. J. Nuclear receptors and lipid physiology: Opening the X-files. Science 2001, 294, 1866-1870.
23. Olefsky, J. M. Nuclear receptor minireview series. J. Biol. Chem. 2001, 276, 36863-36864.
24. Kliewer, S. A.; Lehman, J. M.; Willson, T. M. Orphan nuclear receptors: Shifting endocrinology into reverse. Science 1999, 284, 757-760.
25. Nuclear receptors nomenclature committee. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97, 161-163.
26. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395, 137-143.
27. Westin, S.; Kurokawa, R.; Nolte, R. T.; Wisely, G. B.; McInerney, E. M.; Rose, D. W.; Milburn, M. V.; Rosenfeld, M. G.; Glass, C. K. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 1998, 395, 199-202.
28. Camp, H. S.; Li, O.; Wise, S. C.; Hong, Y. H.; Frankowski, C. L.; Shen, X.; Vanbogelen, R.; Leff, T. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000, 49, 539-547.
29. Rocci, S.; Picard, F.; Vamecq, J.; Gelman, L.; Potier, N.; Zeyer, D.; Dubuquoy, L.; Bac, P.; Champy, M. F.; Plunket, K. D.; Leesnitzer, L. M.; Blanchard, S. G.; Desreumaux, P.; Moras, D.; Renaud, J. P.; Auwerx, J. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 2001, 8, 737-747.
30. Kodera, Y.; Takeyama, K.; Murayama, A.; Suzawa, M.; Masuhiro, Y.; Kato, S. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J. Biol. Chem. 2000, 275, 33201-33204.
31. Kliewer, S. A.; Goodwin, B.; Willson, T. M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 2002, 23, 687-702.
32. Kliewer, S. A.; Moore, J. T.; Wade, L.; Staudinger, J. L.; Watson, M. A. ; Jones, S. A.; McKee, D. D.; Oliver, B. B.; Willson, T. M.; Zetterstrom, R. H. ; Perlmann, T.; Lehmann, J. M. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92, 73-82.
33. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; Ohlsson, R.; Pastlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12208-12213.
34. Staudinger, J. L.; Goodwin, B.; Jones, S. A.; Hawkins-Brown, D.; MacKenzie, K. I.; LaTour, A.; Liu, Y.; Klassen, C. D.; Brown, K. K.; Reinhard, J.; Willson, T. M.; Koller, B. H.; Kliewer, S. A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3369-3374.
35. Xie, W.; Radminska-Pandya, A.; Shi, Y.; Simon, C. M.; Nelson, M. C.; Ong, E. S.; Waxman, D. J.; Evans, R. M. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3375-3380.
36. Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; Williams, S. P.; Willson, T. M.; Kliewer, S. A. The human nuclear xenobiotic receptor PXR; structural determinations of directed promiscuity. Science 2001, 292, 2329-2333.
37. Monolagas, S. C.; Kousteni, S.; Jilka, R. L. Sex steroids and bone. Recent Prog. Horm. Res. 2002, 57, 385-409.
38. Behl, C. Oestrogen as a neuroprotective hormone. Nat. Rev. Neurosci. 2002, 3, 433-442.
39. Hodgin, J. B.; Maeda, N. Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 2002, 143, 4495-4501.
40. Bhathena, S. J.; Velasquez, M. T. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am. J. Clin. Nutr. 2002, 76, 1191-1201.
41. Wiseman, H.; Duffy, R. New advances in the understanding of the role of steroids and steroid receptors in disease. Biochem. Soc. Trans. 2001, 29, 205-209.
42. Gervois, P.; Torra, I. P.; Fruchart, J. C.; Staels, B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin. Chem. Lab. Med. 2000, 38, 3-11.
43. Olsen, N. J.; Kovacs, W. J. Effects of androgens on T and B lymphocyte development. Immunol. Rev. 2001, 23, 281-288.
44. Jones, D. C.; Manning, B. M.; Daynes, R. A. A role for the peroxisome proliferator-activated receptor alpha in T-cell physiology and aging immunobiology. Proc. Nutr. Soc. 2002, 61, 363-369.
45. Watanabe, M.; Yanagi, Y.; Masuhiro, Y.; Yano, T.; Yoshikawa, H.; Yanagisawa, J.; Kato, S. A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem. Biophys. Res. Commun. 1998, 245, 900-905.
46. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; Metzger, D.; Chambon, P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270, 1491-1494.
47. Yanagisawa, J.; Yanagi, Y.; Masuhiro, Y.; Suzawa, M.; Watanabe, M.; Kashiwagi, K.; Toriyabe, T.; Kawabata, M.; Miyazono, K.; Kato, S. Convergence of transforming growth factor-b and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999, 283, 1317-1321.
48. Magae, J.; Illenye, S.; Chang, Y.-C.; Mitsui, Y.; Heintz, N. H. Association with E2F-1 governs intracellular trafficking and polyubiquitination of DP-1. Oncogene 1999, 18, 593-605.
49. Grimaldi, P.; Djian, P.; Negrel, R.; Ailhaud, G. Differentiation of Ob17 preadipocytes to adipocytes: requirement of adipose conversion. EMBO J. 1982, 1, 687-692.